About Vifor pharma
Vifor Pharma: A Global Leader in Iron Deficiency and Anaemia Therapies
Vifor Pharma is a Swiss-based pharmaceutical company that specializes in the development and commercialization of iron deficiency and iron deficiency anaemia therapies. With a history dating back to 1872, Vifor Pharma has established itself as a global leader in the field of iron therapy, providing innovative solutions to patients suffering from these conditions.
The company's roots can be traced back to pharmacist Caspar Friedrich Hausmann, who opened a pharmacy in St. Gallen, Switzerland over 150 years ago. Over time, the business expanded into manufacturing and distribution of pharmaceutical products under the name Galenica Group. In 2007, Vifor Pharma was spun off as an independent entity with a focus on developing treatments for iron deficiency.
Today, Vifor Pharma operates globally with offices across Europe, North America and Asia-Pacific regions. The company's portfolio includes several leading brands such as Ferinject®, Mircera® and Venofer®, which are used by healthcare professionals worldwide to treat patients suffering from iron deficiency anaemia.
Iron deficiency is one of the most common nutritional deficiencies worldwide affecting millions of people every year. It occurs when there is not enough iron in the body to produce haemoglobin - an essential protein found in red blood cells that carries oxygen throughout our bodies. Iron-deficient individuals may experience fatigue, weakness or shortness of breath due to low oxygen levels.
Iron-deficiency anaemia is a more severe form of this condition where there are not enough red blood cells produced due to lack of sufficient iron levels leading to symptoms like pale skin tone or brittle nails among others.
Vifor Pharma's mission is simple - To improve patient outcomes through innovative therapies for those suffering from chronic diseases like Iron Deficiency Anaemia (IDA). The company has invested heavily in research & development (R&D) activities aimed at discovering new treatments for IDA while also improving existing ones through clinical trials conducted across multiple countries around the world.
One such example is Ferinject® - an intravenous (IV) treatment option that delivers high doses of elemental iron directly into patients' bloodstream quickly restoring their depleted stores without causing gastrointestinal side effects commonly associated with oral supplements like constipation or nausea among others.
Another product offered by Vifor pharma is Mircera® which provides long-lasting relief from IDA symptoms by stimulating erythropoietin production within bone marrow cells resulting in increased production rate for red blood cells thus reducing dependence on frequent IV infusions required with other treatments available today making it more convenient for patients who require regular treatment options but cannot visit hospitals frequently due to distance or other reasons
In addition to its core business activities focused on developing innovative therapies for IDA sufferers globally; Vifor pharma also engages actively with various stakeholders including healthcare professionals patient groups regulatory authorities policymakers etc., sharing knowledge about latest developments related specifically towards treating IDA while also advocating better access & affordability options available today so that everyone can benefit equally irrespective socio-economic status geographic location etc.,
Overall,Vifor pharma has established itself as one of the leading companies dedicated solely towards improving patient outcomes through innovative therapies aimed at treating chronic diseases like Iron Deficiency Anaemia(IDA). With its strong commitment towards R&D activities coupled with extensive global reach; it continues playing pivotal role shaping future landscape within this space ensuring better quality life millions affected worldwide every year!
viforpharma.com
